Abstract
Background: ARID1A protein, a component of the SWI/SNF chromatin-remodeling complex, has been implied as a tumor suppressor. It has been reported that decreased expression of ARID1A protein is associated with poor prognosis of gastric cancer. Our study aimed to explore the relationship with ARID1A protein expression and first-line chemotherapy in gastric cancer. Method: A total of 88 advanced gastric cancer patients were enrolled. All the cases had been histologically confirmed as adenocarcinoma. We examined the expressions of ARID1A protein by immunohistochemistry, clinical outcome and response to first-line chemotherapy. Result: Loss of ARID1A protein expression was identified in 17(19.3%) of 88 gastric cancer samples. The most common first-line chemotherapy was oral fluoropyrimidine plus a platinum analog (54.5%), followed by fluoropyrimidine plus a platinum analog with trastuzumab (14.7%) and fluoropyrimidine alone (13.6%). Both progression-free survival of primary chemotherapy and overall survival were not affected by the presence or absence of ARID1A protein expression. Conclusion: ARID1A protein expression statuses did not correlate with progression-free survival of primary chemotherapy in advanced gastric cancer. Background: ARID1A protein, a component of the SWI/SNF chromatin-remodeling complex, has been implied as a tumor suppressor. It has been reported that decreased expression of ARID1A protein is associated with poor prognosis of gastric cancer. Our study aimed to explore the relationship with ARID1A protein expression and first-line chemotherapy in gastric cancer. Method: A total of 88 advanced gastric cancer patients were enrolled. All the cases had been histologically confirmed as adenocarcinoma. We examined the expressions of ARID1A protein by immunohistochemistry, clinical outcome and response to first-line chemotherapy. Result: Loss of ARID1A protein expression was identified in 17(19.3%) of 88 gastric cancer samples. The most common first-line chemotherapy was oral fluoropyrimidine plus a platinum analog (54.5%), followed by fluoropyrimidine plus a platinum analog with trastuzumab (14.7%) and fluoropyrimidine alone (13.6%). Both progression-free survival of primary chemotherapy and overall survival were not affected by the presence or absence of ARID1A protein expression. Conclusion: ARID1A protein expression statuses did not correlate with progression-free survival of primary chemotherapy in advanced gastric cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
